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Abstract
Investigation of Molecular Functions of Zinc Finger Protein (ZNF71) in NonSmall Cell Lung Cancer
Rehab Mohamed

Non-small cell lung cancer (NSCLC) is the first cause of tumor-related death worldwide.
Despite the advancement in surgical and medical treatment, the prognosis of the disease remains
poor1. To date, there is no available molecular assay to predict the benefit of therapy or
tumor recurrence 2. ZNF71 was reported in our previous study, which identified a 7-gene
predictive signature for the clinical benefit of chemotherapy and prognosis in NSCLC2.
The study concluded that patients who have higher ZNF71 protein expression have better
survival. For this reason, we decided to study the molecular function of ZNF71 and how it
may affect apoptosis, proliferation, and/or epithelial-mesenchymal transformation (EMT) in
NSCLC. The study is restricted by the regulations of COVID-19 social distancing, so many
experiments were stopped and recommended for future work. We used a Taxol-resistant cell
line H460-R derived from the Taxol-sensitive H460-P NSCLC cell line to compare the
level of ZNF71. H460-P cells express a higher level of ZNF71 mRNA, and Taxol induces it
slightly. Also, we found that the ZNF71 mRNA level is higher among epithelial NSCLC, and
lower in mesenchymal-like-cells. Furthermore, KRAB containing ZNF71 is expressed
dominantly in mesenchymal NSCLC, while KRAB-less ZNF71 is expressed in both
mesenchymal and epithelial and its level is always higher than KRAB isoform except for in
H460-R cells. This suggests that a KRAB to KRAB-less ratio could has a role in the cells'
fate and the patients' prognosis, but further studies are required and recommended.

DEDICATION
To the spirit of the women who raised me, my maternal grandmother, who has been a rock of
stability throughout my life;
My parents, whose loving spirit sustains me still;
And to my husband, for unlimited support in my life; And to my kids who provide me the feeling
of happiness of motherhood.

iii

ACKNOWLEDGMENTS
First and foremost, I would like to especially thank my mentor and committee chairperson Dr.
Lan Guo for all the support and guidance she provided for my academic, research and
professional development. Also, for her caring guidance and help in writing my thesis.
I appreciate the guidance and comments which I have received from my supervising committee
members, Dr. Tim Eubank and Dr. Alexey Ivanov. For their invaluable support, and valuable
advice and suggestions.
Special thanks for Dr. Clay Marsh, for his valuable suggestions and advice.
I would like to express my sincere gratitude to Dr. Marieta Gencheva, a scientist in the Eubank
laboratory, Health Science Center in WVU, for her invaluable support, guidance, patience and
valuable suggestions throughout my master’s work
I would like to say thanks to my friend and lab mate, Qing Ye. As well as to the whole Eubank
lab members, Dr. Elena Pugacheva and her lab members, Dr. Siva Kolluri and Dr. Ivan Martinez
and his lab members for providing us with some cell lines during our research.
Last, but far from least, I would like to express my deep appreciation, gratitude, and love for my
husband who supported me throughout this journey. Without him, I could have never made it to
where I am today.

iv

Contents
Abstract ......................................................................................................................................... iii
DEDICATION .............................................................................................................................. iv
ACKNOWLEDGMENTS .............................................................................................................. v
Contents......................................................................................................................................... vi
LIST OF FIGURES ...................................................................................................................... vii
CHAPTER 1: LITERATURE REVIEW ........................................................................................ 1
1.1 Zinc Finger Proteins and tumors ........................................................................................... 3
1.2 Zinc finger protein 71(ZNF71) ............................................................................................. 4
CHAPTER 2: METHODOLOGY .................................................................................................. 6
2.1. Cell Lines and Culture ......................................................................................................... 6
2.2. ZNF71 Gene Knockdown and Overexpression ................................................................... 6
2.3 Quantitative Real Time Polymerase Chain Reaction qRT-PCR .......................................... 7
2.4 Western Blot Assay.............................................................................................................. 8
2.5 Annexin V and Propidium Iodide Assay ............................................................................. 8
2.6 Statistical Analysis ............................................................................................................... 8
CHAPTER 3: RESULTS AND DISCUSSION.............................................................................. 9
3.1 H460-R Cells are Highly Resistant to Taxol Treatment ....................................................... 9
3.2. Validation of the ZNF71 Antibodies by Overexpression of the Protein ............................. 9
3.3. ZNF71 mRNA Levels are Higher in H460-P than in H460-R........................................... 10
3.4 H460-R Cells Response to Taxol Treatment Slightly Affected by Changing the Levels of
ZNF71 ................................................................................................................................ 11
3.5. ZNF71 is Expressed in Different Amounts in Different non-Small Cell Lung Cancer Cells
................................................................................................................................................... 12
CHAPTER 4 ................................................................................................................................. 15
4.1 Conclusions ......................................................................................................................... 15
4.2 Future Plans ........................................................................................................................ 15
References .................................................................................................................................... 17

v

LIST OF FIGURES
Figure 1. 1 Schematic Figure Represents The Structure Of C2H2, RING, PHD, And LIM Zinc
Finger Domains. ............................................................................................................. 2
Figure 1. 2 KRAB-ZNF structure, KRAB-A and KRAB-B located at N-terminus. DNA binding
motifs ............................................................................................................................. 3
Figure 1. 3. Schematic figure explain the structure of KRAB and KRAB-less ZNF71 isoforms .. 4
Figure 3. 1. H460-R cells are Taxol-resistant. H460-P (A) and H460-R (B) cells were treated either
with DMSO or Taxol with the indicated doses. ............................................................. 9
Figure 3. 2: ZNF71 antibodies validation. .................................................................................... 10
Figure 3. 3: Comparison of the ZNF71 mRNA level in resistance cells H460-R and parental cells
H460-P ......................................................................................................................... 11
Figure 3. 4 Effect of ZNF71 gene knockdown on H460-R cells response to Taxol..................... 12
Figure 3. 5 .A. ZNF71 level is different in epithelial and mesenchymal cell lines. ..................... 13
Figure 3. 6 Relative expression ZNF71 mRNA isoform among different NSCLC cell lines. ..... 14

vi

CHAPTER 1: LITERATURE REVIEW
Zinc finger proteins (ZNF) are the largest family of proteins not only in human cells but
also in most eukaryotes, representing about 3% of the total human genome1. They were discovered
for the first time in 1982 by Miller and Klug while studying the transcription factor IIIa (TF IIIa)
in Xenopus Laevis1,2. The authors observed and discovered a novel repeating motif within the
protein, which was later named zinc finger1—composed of histidine and cysteine amino acids
coordinated by zinc ions. This motif has the ability to bind to DNA, RNA, and other cellular
proteins3. Therefore, ZNFs have a wide range of functions according to their molecular structure
and binding site. ZNFs can be involved in DNA repair, degradation of proteins, signal
transductions, migration of cells, regulation of apoptosis, lipid binding, and transcription
regulation3,2. There are many subtypes of ZNFs classified according to different combinations of
cysteine and histidine coordinated by zinc ion. The most common one is named C2H2 ZNF, and
is composed of two histidines in one chain and two cysteines in another chain coordinated by zinc
ion, in the form of C-x-C-x-H-x-H. The domain functions by binding to specific DNA sequences.
The primary contact made by the alpha helix that binds to the major groove of the DNA through
primary hydrogen bond interaction from positions 1, 3 and 6 to three successive bases, figure 1.2,
and through secondary interaction from position 2. There is a highly conserved linker region
TGEKP in almost half of C2H2 zinc finger protein that are believed to play a role in the affinity
of ZNF to bind DNA2. Other less common zinc finger domain types include RING, PHD, and
LIM, figure 1.1. Really Interesting New Gene (RING) are a group of proteins which include the
RING-motif C-x-C-x-C-x-H-x-C-x-C-x-C-x-C. E3 ubiquitin ligases are among the proteins
belonging to this group, one of which is the mouse double minute2 MDM2 gene, believed to be
involved in cancer progression3. The Plant Homeodomain PHD is a motif which has the ability to
remodel the chromatin through epigenetic modification. Lin-11, Isl-11 and Mec-3 LIM class play
an important role in actin and cytoskeletal interaction as well as focal adhesion3.
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Figure 1. 1 Schematic Figure Represents The Structure Of C2H2, RING, PHD, And LIM Zinc Finger Domains.
3

The most exciting subgroup of the ZNF proteins are the Krupple-associated box domain
zinc finger protein (KRAB-ZNF).
KRAB-ZNF are a family of transcriptional repressors with a diverse array of functions,
most notably the silencing of transposable elements4. They contain an N-terminal KRAB domain
and a C-terminal C2H2 zinc finger group. The KRAB domain is composed of around 75 amino
acids5, and there are two types of KRAB domains; KRAB box A, which is known to be responsible
for the repressive activity of the zinc finger, and box B, the function of which is to aid the action
of box A. Both boxes are located at the N-terminus of the zinc finger 1.2. The repressor action of
KRAB-ZNF requires the recruitment of KRAB Associated Protein 1, also know Tripartite Motif
Protein 28, KAP1/TRIM28.

2

Figure 1. 2 KRAB-ZNF structure, KRAB-A and KRAB-B located at N-terminus. DNA binding motifs located at
C-terminus6, ZNFs binds DNA through primary hydrogen-bond interactions from helical positions 1,3, and 6.

KAP1 functions as a scaffold complex composed of histone methyl transferase (SETDB1),
Heterochromatin Protein-1 (HP-1), Nucleosome Remodeling and Deacetylation (NuRD), and
DNA Methyl Transferase6. When KRAB-ZNF recruits KAP-1, the repressor complex formed
leads to heterochromatin formation. On the other hand, ZNFs bind to DNA mainly through their
C- terminus domain which comprises primarily of tandem repeats with the motif (CX
HX

2-6

2-4

CX
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H), this activity starts as early as the first few days of embryonic life, results in

transgenerational imprinting.
1.1 Zinc Finger Proteins and tumors
Since the KRAB domain binds directly to KAP1, most of the suppressive functions of
KRAB-ZNF is mediated through KAP1. The role of KAP1 in cancer has just emerged in the field.
Using microarray analysis, KAP1 expression level was found to be increased with the increase of
the clinical phase of breast tumors7. Also, overexpression of many KRAB-ZNFs and KAP1 in
breast tumors was reported, while knockdown of KAP1 led to a suppression of tumor cells
proliferation, growth, and metastasis. Furthermore depletion of KAP1 led to a decrease in the
expression KRAB-ZNF proteins8. There are many other studies ongoing to find out the effect of
zinc finger proteins on the prognosis of non-small cell lung cancer patients. RB-associated KRAB
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zinc finger (BRAK) interacts with the tumor suppressor retinoblastoma gene, RB. The RBAK is
upregulated in non-small cell lung cancer (NSCLC) and has a potential effect on tumor cells
migration and invasion. Furthermore, higher expression of RBAK was found to be associated with
short survival in cancer patients (NSCLC)8. On the other hand, zinc finger protein 668 (ZNF668)
protein expression is down regulated in tumor tissue in comparison to surrounding normal lung
tissue. It also was found to be down regulated in lymph nodes metastasis phase, and restoration of
ZNF668 expression led to down regulation of Snail and increase E-cadherin protein level9.
1.2 Zinc finger protein 71(ZNF71)
ZNF71 is a member of the Krupple C2H2-types zinc finger protein family. It has two
isoforms derived by alternative splicing, a 489 AA short isoform and a 549 AA long isoform. The
two isoforms differ by the inclusion of an alternative exon, which results in inclusion of a KRAB
domain in the long isoform. Both ZNF71 isoforms contain identical C-termini comprising 13
C2H2 type zinc finger, as shown in figure 1.3.

Figure 1. 3. A, schematic figure explaining the structure of KRAB and KRAB-less ZNF71 isoforms. KARB
domain was labeled with a red box. B, ZNF71 gene location in long arm of chromosome 19.

ZNF71 was first identified by Mataki et al. as a zinc finger protein induced by TNF alpha
in human umbilical vein endothelial cells10. It was named EZFIT, Endothelial Zinc finger protein
Induced by TNF alpha. In this study, ZNF71 was shown to be expressed at a high level in placenta,
with expression also detected in brain, testis, pancreas, heart, small intestine, muscle, uterus,
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prostate and peripheral blood leukocytes. Tissues which did not express ZNF71 were liver, lung,
colon, stomach, the salivary gland, and the thyroid gland. ZNF71 was also reported in our previous
study which identified a 7-gene predictive signature for clinical benefit of chemotherapy and
prognosis in NSCLC11. Prior to our study, there were no available predictive molecular assays to
speculate the benefits of chemotherapy or the risk of tumor recurrence in NSCLC patients.
Therefore, our study aimed to develop a multi-gene assay to predict the clinical benefits of the
chemotherapy for patients who suffer from NSCLC. A total of 160 genes were identified from a
microarray analysis, and the mRNA expression of these genes were analyzed using qRT-PCR.
Using independent validation patient cohorts, a 7-gene signature was identified from the training
cohort. Within this model, patients were stratified into two prognostic groups with distinct postsurgical disease-specific survival and recurrence-free survival. To validate the functional
involvement of the identified 7-gene signature, immunohistochemistry staining (IHC) was used to
evaluate the protein expression of these biomarkers. The antibodies to biomarkers with good
quality in formalin fixed paraffin embedded (FFPE) NSCLC tissues were further quantified with
Automated Quantitative Analysis (AQUA) on tissue microarrays (TMA) constructed at Yale
Pathology Laboratory. For ZNF71 protein, an AQUA score cutoff point was identified to define a
patient’s prognostic stratification. It was concluded that patients with higher protein expression
have better survival, and the protein expression of ZNF71 was concordant with its mRNA
expression in independent NSCLC patient cohorts that the higher mRNA expression of ZNF71
was associated with better patient survival and chemo-sensitivity to traditional therapy of NSCLC
(Taxol + platinum based therapy)11. Furthermore, there was a 7% loss of DNA copy number in
NSCLC tissue in comparison to normal lung tissue11. All of the evidence suggest the importance
of ZNF71 as a prognostic marker, or even a novel therapeutic target in the future. For this reason,
we decided to study the molecular functions of the ZNF71 gene, and how it may affect
proliferation, apoptosis, EMT, and/or chemotherapy response in NSCLC cells.
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CHAPTER 2: METHODOLOGY
2.1. Cell Lines and Culture
Primary cell lines and non-small cell lung cancer (NSCLC) cells used in this project
include; Human Small Airway Epithelial Cells (SAEC) were maintained in Small Airway
Epithelial Cell Growth Medium BulletkitTM SAGMTM medium (Lonza, catalog number CC-3118).
Human Bronchial/ Tracheal Epithelial Cells with Retinoic Acid (NHBE) cells were maintained in
Bronchial Epithelial Cell Growth Medium BulletKitTM BEGMTM medium (Lonza, catalog
number CC-3170), H358, H441, H820, H1395, H23, H513, H1299, and A549 NSCLC cells were
all maintained in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% of fetal
bovine serum and 1% penicillin/streptomycin. H460 large cell lung cancer cells (H460-P) and its
derivative H460-R12, which are resistant to Taxol treatment, were kindly provided by Dr.Siva
Kumar Kolluri, the Siva Kolluri laboratory at the Oregon State University as part of their
collaboration with the Guo laboratory. These cell groups were maintained in Roswell Park
Memorial Institute (RPMI-1640) medium, supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin. All primary and non-small cell lung cancer cells were incubated at 37Co
and 5% CO2 concentration.
2.2. ZNF71 Gene Knockdown and Overexpression
For knockdown purposes, we used a pool of three target-specific 19-25 nucleotide length
ZNF71 siRNAs, purchased from Santa Cruz Biotechnology (catalog number SC-77001). As
scrambled controls, we used control siRNA-A (catalog number SC-37007) and control siRNA-D
(catalog number SC-44232). H460 cells were plated in six-well plates at 250,000 cells per well
and were transfected after 24-48 hours, when cells confluence reached ~ 60-70%. Transfection
was performed with Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) in
Opti-MEMTM reduced serum medium (Thermo Fisher Scientific), according to manufacturer’s
protocol RNA was isolated 72 hours post-transfection.
For overexpression purposes, the ZNF71 Plasmid construct was purchased from the
PlasmID database (https://plasmid.med.harvard.edu/PLASMID/OrderOverview.jsp) maintained
by Harvard University (catalog number HsCD00412101), ZNF175 plasmid construct used as a
control (catalog number HsCD00421069), and pLU-GFP vector was also used as a control. For
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HEK-293T cell transfection, calcium phosphate was used as a transfection reagent, which is
commonly used to introduce DNA into eukaryotic cells to obtain both transient and permanent
transfections. The approach is based on mixing HEPES-buffered saline containing Na3PO4 with
CaCl2 containing the DNA. The DNA calcium phosphate stick to the cell membrane then is taken
by cellular endocytosis. For the NSCLC transfection reagent, Lipofectamine was purchased from
Thermo Fisher Scientific (catalog number L3000008). Cells were cultured in six-well plates
seeding 400,000-500,000 cells per plate according to the transfection type; reverse, serum-free
medium, or regular transfection. 15 µg of plasmid in 50 µl CaCl was used to transfect HEK-293
in a 35x10 mm cell culture dish.
2.3 Quantitative Real Time Polymerase Chain Reaction qRT-PCR.
Total RNA was extracted from various cell lines using the RNeasy Mini kit (Qiagen).
According to manufactures’ protocol, RNA was eluted in 30 µl deionized water and kept at -80oC
until use. Concentration of RNA was determined with NanoDrop, and RNA purity was verified by
determining the A260/A230 ratio. One microgram of total RNA was reverse transcribed using
SuperScriptIII First Strand Synthesis SuperMix for qRT-PCR (Invitrogen). For quantitative real
time PCR, either SYPR Select Master Mix (Thermo Fisher) or TaqMan master mix (IDT) was
used, depending on the primers/probes used. All primers were purchased from IDT. There are
three sets of ZNF71 primers:
Set1 (will amplify both isoforms of the gene) primer F: 5'- CAGCACTTCAGACCTCAGTAAG3', primer R: 5'-TTGGTGCTTTATCAGGGACG-3’, Set 2, KRAB-Less ZNF71, primer F: 5'GCCTGTCTTCCTATTCACCG-3’, primer R: 5'-CATTTCAGGTCTAGTCTCCCAG-3’, probe:
/56-FAM/AGC CAT CCC /ZEN/TCT GCT GCC C/3IABkFQ/
Set3,

KRAB-ZNF71,

primer

F:

5'-

GACGTTCAGGGATGTGACTG-3',

primer

R:

5'TTCAGGTCTAGTCTCCCAGTC-3', probe: /56-FAM/AGG TCC TTC /ZEN/TGG GCA GGC
TC/3IABkFQ/.
The PCR reactions were loaded in a 384-well plate in triplicate. The expression level of ZNF71
was calculated using the Comparative Threshold (2^-ddCt) method and normalized to UBC or RPL4
housekeeping genes. UBC primer set, primer F: 5’-GATTTGGGTCGCAGTTCTTC-3’, primer R:
5’-CCTTATCTTGGATCTTTGCCTTG-3’. RPL4 (Cat. N PPH13915A SABiosciences)13. For
SYBR Green, PCR melting curve analysis was performed to verify the reactions had a single
product.
7

2.4 Western Blot Assay
Cells were lysed in Gel Lysis Buffer (GLB), GLB composed of 50 mM Tris-HCl, pH 6.8,
2% SDS, 10% Glycerol. Total protein was quantified using the BCA assay (Pierce). An equal
amount of protein lysate (20-30 µg) was loaded and separated on 4-12% Bis-Tris gels, then
transferred to polyvinylidene difluoride (PVDF) membrane (Fisher). ZNF71 antibodies were
purchased from Sigma Aldrich (Cat No. AV39497), and GeneTex (Cat No. GTX116553).
Standard chemiluminescence was used to detect the protein bands.
2.5 Annexin V and Propidium Iodide Assay
Cells were seeded in six-well plates at 250,000-500,000 cells per well, then treated with 1,
5, 10, or 50 nM Taxol either 24 hours post-plating or 72 hours post ZNF71 siRNA transfection.
DMSO was used as a vehicle control. An Annexin V binding assay was performed using the FITC
Annexin V/Dead Cell Apoptosis Kit with FITC Annexin V and PI for flow cytometry (Invitrogen).
PI is the standard reagent to exclude non-viable cells from flow cytometry assay, i.e., to calculate
cell death. Flow cytometry was performed at the Flow Cytometry and Single Cell Core Facility at
WVU on the LSRFortessa machine.
2.6 Statistical Analysis
A mixed effect model was used to assess the difference between two conditions, using R
package Ime4. Linear mixed-effect model were used to assess the difference between different
conditions as fixed effects (biological samples as random effects), taking into account the
correlation between technical replicate. The p-value was calculated based on asymptotic Zdistribution.
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CHAPTER 3: RESULTS AND DISCUSSION
3.1 H460-R Cells are Highly Resistant to Taxol Treatment
Since we were interested to study the role ZNF71 plays in chemotherapy resistance in lung
cancer, we wished to verify that we have a cell culture model of chemo-resistance. We employed
H460-P cells, which are sensitive to Taxol, and a derivative cell line, H460-R, reported to be Taxol
resistant. Both H460-R and H460-P were plated in 6-well plates in three biological replicates and
incubated with either 10 nM or 50 nM Taxol for 48 hours, with DMSO used as vehicle control.
Supernatants were centrifuged to collect floating cells which were combined with trypsinized cells
and subsequently stained with Annexin V and PI. Percentage of apoptotic/dead cells was
determined by flow cytometry. As shown in figure 3.1(A), after 48 hours DMSO treatment, the
percent of live H460-P cells is 88.5%, but drops after treatment with 10 nM Taxol to 34% and as
low as 27% when the cells are treated with 50 nM Taxol. In contrast, the percent of live H460-R
cells is 77.5% and 64% when treated with 10 nM and 50 nM Taxol, respectively (fig.3.1B). In
conclusion, we confirmed that H460-R cells are resistant to Taxol treatment.

Figure 3. 1. H460-R cells are Taxol-resistant. H460-P (A) and H460-R (B) cells were treated either with DMSO
or Taxol with the indicated doses. After 48 hours, the cells were stained with Annexin V and PI and the percent
of live/dead cells was determined by flow cytometry. Error bars represent standard deviation from three biological
replicates. A mixed effect model was used to assess the difference between two conditions, using R package Ime4.
The p-value was calculated based on asymptotic Z-distribution

3.2. Validation of the ZNF71 Antibodies by Overexpression of the Protein
We wished to validate the ZNF71 antibodies purchased from Sigma and GeneTex used in
our experiments since there are no published data on their specificity. First, the specificity of the
antibodies was examined by knocking down ZNF71; this process compares the antibody bands of
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knocked down cells to the wild type cell signal. We were unable to detect the endogenous ZNF71;
for this reason, we next elected to overexpress ZNF71 to determine whether the antibodies
recognize ZNF71 protein. HEK-293 cells were transfected with ZNF71 expression tagged with V5
as well as with plasmids expressing GFP, ZNF175, and ZNF263 controls. The overexpression was
validated with qRT-PCR assay. As shown in figure 3.2 (A), the ZNF71 mRNA expression is about
200 times higher in the ZNF71-overexpressing cells than in the control cells. Both ZNF71
antibodies detected a protein band corresponding to ZNF71 detected and matched the signal of
anti-V5 antibody (Fig.3.2.B) while no signals were detected in any control group. We conclude
that while both ZNF71 antibodies purchased from Sigma and GeneTex cannot detect endogenous
levels of ZNF71 protein, they can detect the higher level of ZNF71 by overexpression.

Figure 3. 2: ZNF71 antibodies validation. A qRT-PCR assay was performed to measure ZNF71 mRNA
expression. Error bars represent standard deviation from three technical replicates. B. ZNF71 protein detection
by two antibodies from Sigma and GeneTex. The band was confirmed by the V5 antibody that labeled the
plasmid. GAPDH is a loading control.

3.3. ZNF71 mRNA Levels are Higher in H460-P than in H460-R
Once we confirmed the resistance of H460-R cells to Taxol, our next experiment was to
study whether there is a difference in the ZNF71 mRNA level between the resistant and parental
cells. The two cell lines were plated in six-well plates in six biological replicates. For DMSO and
Taxol treatment, H460-P and H460-R cells were plated in three biological replicates. RNA was
collected from each replicate for qRT-PCR, (see Methodology) as shown in figure 3.2(A). The
ZNF71 mRNA level is higher in the H460-P cells, even when the cells were treated with Taxol,
(Fig.3.2.B). It was also noted that the ZNF71 mRNA levels increase with Taxol treatment.
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Figure 3. 3. A. Comparison of the ZNF71 mRNA levels in resistant cells, H460-R, and parental cells, H460-P.
Six biological replicates for H460-P and H460-R were plated. RNA was isolated and subjected to qRT-PCR. B.
Both H460-P and H460-R cells were treated with either Taxol or DMSO, then the level of ZNF71 mRNA was
quantified by qRT-PCR. Error bars represent three biological replicates. ZNF71 mRNA levels are higher in
H460-P; Taxol treatment leads to slight increase in the level of ZNF71 mRNA. A mixed effect model was used to
assess the difference between two conditions, using R package Ime4. The p-value was calculated based on
asymptotic Z-distribution

3.4 H460-R Cells Response to Taxol Treatment Slightly Affected by Changing the Levels of
ZNF71
To study whether we observe a direct impact on the cells' response to Taxol chemotherapy,
ZNF71 was knocked down using ZNF71 siRNA. After 72 hours, the cells were treated with either
vehicle control DMSO, 10 nM or 50 nM Taxol. After further 48 hours treatment with Taxol, the
cells were stained with Annexin V and PI to measure the apoptotic cell death. As shown in figure
3.3, the cells response to chemotherapy was slightly affected by ZNF71 knockdown, cell survival
increased and cell death decrease after ZNF71 gene knockdown with respect to the treatment
doses. For this experiment, we planned to redesign it in a way that we can collect RNA at the time
of transfection instead of after exposure to Taxol to measure the knockdown effectiveness, and
correlate it to the cellular response to Taxol. Unfortunately, as many other experiments- explained
later in Restrictions and Limitations section- this work was stopped because of COVID-19 social
distancing regulations.
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Figure 3. 4 Effect of ZNF71 gene knockdown on H460-R cells response to Taxol. H460-R cells were transfected
with ZNF71 or scrambled control siRNAs and after 72 hours the cells were treated with either DMSO, 10 nM, or
50 nM Taxol for 48 hours. Cells were collected and stained with Annexin V and PI and percent of live, apoptosis,
and dead cells were determined by follow cytometry. The ZNF71 knockdown had a mild effect on the Taxol
response of the cells. A mixed effect model was used to assess the difference between two conditions, using R
package Ime4. The p-value was calculated based on asymptotic Z-distribution

3.5. ZNF71 is Expressed in Different Amounts in Different non-Small Cell Lung Cancer Cells
We performed an experiment to determine the level of expression of ZNF71 in various
NSCLC cell lines. Multiple NSCLC were plated in six wells plates at a confluence of 80%, then
mRNA and the protein were purified from each cell line. We quantified the mRNA using qRTPCR, using NHBE cells as a control for the cancer group. We also performed a Western blot to
determine the ZNF71 protein level using overexpressed ZNF71 in HEK-293 cells as a control. The
endogenous level of the protein was not detectable in any of the cell lines tested, with only nonspecific bands appearing on the membrane. Next, we classified the cell lines as either mesenchymal
or epithelial according to the signals detected by the Western blot using known mesenchymal and
epithelial markers, like ZEB1 for mesenchymal and E-Cad for epithelial cells. As shown in figure
3.5, the cells are divided into three groups, 1) epithelial cell lines, NHBE, H358, H441, H513, and
H820; 2) mesenchymal cell lines, H23, H460, and H1299, and, 3) mostly mesenchymal cell lines,
A549 and H1395. Next we compared the level of ZNF71 mRNA expression between these cell
groups. The level of ZNF71 was relatively higher among epithelial cells, lower among the
mesenchymal group, and intermediate in the mostly-mesenchymal cells group. There was a plan
to repeat this experiment with plating every cell line in four biological replicates, three replicates
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to be used to collect the RNA, and the fourth for protein. Unfortunately, COVID-19 social
distancing regulations stopped us from finishing this experiment.

Figure 3. 5. ZNF71 level is different in epithelial and mesenchymal cell lines. A, ZNF71 mRNA levels among
different NSCLCs. B, Anti-ZNF71 antibodies detect overexpressed but not the endogenous protein level in
NSCLC cell lines. Classification of NSCLC cells according to epithelial and mesenchymal markers, some cell
lines express E-Cadherin (epithelial), other express ZEB1 (mesenchymal), while mostly mesenchymal neither
express E-Cad nor ZEB1. C, ZNF71 mRNA levels are higher in epithelial cell lines either when compared to
combined mesenchymal and mostly mesenchymal or D, when compared to mesenchymal and mostly
mesenchymal separately.

3.6 The KRAB-ZNF71 Isoform is Expressed Mainly in Mesenchymal NSCLC Cells While
the KRAB-Less Isoform Is Expressed in the all Cell Lines, Including Primary NonCancerous Cells.
Because of the importance of KRAB-ZNF and its relation to some tumor recurrence and
metastasis, we decided to determine the relative ratio of the two isoforms in different cell lines.
We designed three sets of primers that amplify either both isoforms, or the KRAB isoform and
KRAB-less isoform separately. First, we measured in which cell line each isoform was expressed
and what was the relationship between KRAB-ZNF71 isoform and mesenchymal-epithelial cell
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lines. As shown in figure 3.6, mostly mesenchymal NSCLC cells express both the KRABcontaining and KRAB-less isoforms, while the epithelial cells express only the KRAB-less
isoform. Also, in most of the cell lines, the KRAB-less ZNF71 level was higher than the KRABZNF71 except for H460-R, which was derived from H460-P. In this cell line, the level of the
KRAB isoform is much higher than the level of the KRAB-Less isoform. This could be related to
the cells resistance to Taxol and it could be induced by Taxol when the cells were treated with it
at the time of developing resistance to Taxol. The next experiment planned was to knock down
and overexpress the KRAB-ZNF71 isoform in one cell line per mesenchymal, epithelial, and
mostly mesenchymal cell groups, then study the effect of this gene manipulation on the epithelial
and mesenchymal markers expression in these cells. Moreover, studying the response of the cell
to Taxol after transfection was also planned. This plan was prevented by the rule of COVID1social distancing.

Figure 3. 6 Relative expression ZNF71 mRNA isoform among different NSCLC cell lines. qRT-PCR with
primers detecting either the KRAB-less or KRAB-containing ZNF71 isoforms. KRAB-ZNF71 is detected
predominantly in mesenchymal cells. Increase the power of the experiment by growing every cell line in three
biological replicates to get the statistical significance. Error bars represent the technical replicates.
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CHAPTER 4
4.1 Conclusions
ZNF71 is one of the KRAB zinc finger protein family which could be associated with
tumor prognosis and patients outcomes. It also reported in our previous study that patients with
higher protein expression have better survival and chemo-sensitivity to the chemotherapy. In this
project, we studied the molecular functions of ZNF71 in NSCLC. ZNF71 mRNA was expressed
slightly higher in H460-P cells than H460-R cells with concordant to our previous study, which
indicates the higher level of ZNF71 the better patients’ survival and better respond to
chemotherapy. Furthermore, we interested in the finding that total ZNF71 mRNA is higher in
epithelial than in mesenchymal NSCLC cell lines, and we planned further molecular and
bioinformatics investigations. KRAB containing ZNF71 was expressed predominantly in
mesenchymal NSCLCs, while KRAB-less ZNF71 expressed in both mesenchymal and epithelial
NSCLC. KRAB-less ZNF71 mRNA level is higher than KRAB-ZNF71 in all studied cell types
except in H460-R cells which could be related to Taxol resistance. Because of the regulation of
COVID-19 social distancing, many experiments were recommended to be resumed at later date to
study the gene further.
4.2 Future Plans
1. Clone KRAB containing plasmid for over expression experiment.
2. Design KRAB-ZNF71 siRNA specific to the exon coding for KRAB domain for gene
knock down experiments.
3. Repeat the redesigned experiment of the ZNF71 manipulated cells. In a future experiment,
we will use the KRAB-ZNF71 siRNA, and the cells will be plated in 6-well plates, with
every group in three biological replicates. RNA will be isolated 48-hours post transfection.
Further, transfected cells will be treated with 10 nM Taxol for 48 hours. The cells will then
be stained with Annexin V and PI to calculate the percentage of the live, apoptotic, and
dead cells.
4. Overexpression of KRAB containing ZNF71, collect RNA and treat the cells with Taxol
48 hours post transfection. After 48 hours treat the cells with Taxol and collect the cells for
Annexin V and PI staining to measure live, apoptotic, and dead cells.
5. Repeat the experiment for ZNF71 level and KRAB-ZNF71 in three biological replicates.
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What I have learned during my study in the program?
• Cell culture.
• Cellular transfection and gene knockdown
• Protein overexpression
• RNA isolation using both Trizol and centrifugation techniques
• cDNA synthesis
• qRT-PCR assay
• MTT assay
• Western blot assay
• Annexin V and PI staining and flow cytometry
• I learned how to read scientific papers
• Scientific writing
Classes taken during my course work
• Foundations 1 and 2
• Scientific integrity
• Cellular methods
• Molecular Genetic
• Cancer cell Biology
• Scientific Writing
• Cancer Pharmacol/Theraputics
• Biomedical/ Oncogenic signaling
• Journal Clubs

16

References
1.

Klug A. The discovery of zinc fingers and their development for practical applications in
gene regulation and genome manipulation. Q Rev Biophys. 2010.
doi:10.1017/S0033583510000089

2.

Laity JH, Lee BM, Wright PE. Zinc finger proteins: New insights into structural and
functional diversity. Curr Opin Struct Biol. 2001. doi:10.1016/S0959-440X(00)00167-6

3.

Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell
Death Discov. 2017. doi:10.1038/cddiscovery.2017.71

4.

Chew A. The role of KRAB-ZFPs in transposable element repression and mammalian
evolution. Q Rev Biol. 2017;82(3):251-255. doi:10.1086/519967

5.

Peng H, Begg GE, Harper SL, Friedman JR, Speicher DW, Rauscher FJ. Biochemical
analysis of the Kruppel-associated box (KRAB) transcriptional repression domain:
Spectral, kinetic, and stoichiometric properties of the KRAB·KAP-1 complex. J Biol
Chem. 2000;275(24):18000-18010. doi:10.1074/jbc.M001499200

6.

Ecco G, Imbeault M, Trono D. KRAB zinc finger proteins. Dev. 2017.
doi:10.1242/dev.132605

7.

Ho J, Kong J, Choong L, et al. Novel Breast Cancer Metastasis-Associated Proteins
research articles. 2009:583-594. doi:10.1021/pr8007368

8.

Addison JB, Koontz C, Fugett JH, et al. KAP1 promotes proliferation and metastatic
progression of breast cancer cells. 2015;75(2):344-355. doi:10.1158/0008-5472.CAN-141561.KAP1

9.

Zhang X, Jiang G, Wu J, Zhou H. Zinc finger protein 668 suppresses non-small cell lung
cancer invasion and migration by downregulating Snail and upregulating E-cadherin and
zonula occludens-1. 2018:3806-3813. doi:10.3892/ol.2018.7802

10.

Mataki C, Murakami T, Umetani HM, Youichiro T, Ishii M, Kodama S. Finger Protein
Induced mRNA in Human Necrosis Umbilical Factor a Vein Endothelial is Profoundly by
Tumor Hiroyuki Takao Masami scription ( Ambion ) was performed with biotinylated
UTP and CTP ( Enzo Diagnostics ), resulting in 40- to 80-fold linear amplif. J Atheroscler
Thromb. 2000;7.

11.

Lan N, Dowlati A, Raese RA, et al. EBioMedicine A Predictive 7-Gene Assay and
Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine.
2018;32:102-110. doi:10.1016/j.ebiom.2018.05.025

12.

Pearce MC, Gamble JT, Kopparapu PR, et al. Induction of apoptosis and suppression of
tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer
cells. 2018;9(40):26072-26085.

13.

Dakhlallah DA, Wisler J, Gencheva M, et al. Circulating extracellular vesicle content
reveals de novo DNA methyltransferase expression as a molecular method to predict
septic shock. J Extracell Vesicles. 2019;8(1). doi:10.1080/20013078.2019.1669881

17

